53
|
Rivetti C, Allen TEH, Brown JB, Butler E, Carmichael PL, Colbourne JK, Dent M, Falciani F, Gunnarsson L, Gutsell S, Harrill JA, Hodges G, Jennings P, Judson R, Kienzler A, Margiotta-Casaluci L, Muller I, Owen SF, Rendal C, Russell PJ, Scott S, Sewell F, Shah I, Sorrel I, Viant MR, Westmoreland C, White A, Campos B. Vision of a near future: Bridging the human health-environment divide. Toward an integrated strategy to understand mechanisms across species for chemical safety assessment. Toxicol In Vitro 2019; 62:104692. [PMID: 31669395 DOI: 10.1016/j.tiv.2019.104692] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Revised: 09/25/2019] [Accepted: 10/14/2019] [Indexed: 12/31/2022]
Abstract
There is a growing recognition that application of mechanistic approaches to understand cross-species shared molecular targets and pathway conservation in the context of hazard characterization, provide significant opportunities in risk assessment (RA) for both human health and environmental safety. Specifically, it has been recognized that a more comprehensive and reliable understanding of similarities and differences in biological pathways across a variety of species will better enable cross-species extrapolation of potential adverse toxicological effects. Ultimately, this would also advance the generation and use of mechanistic data for both human health and environmental RA. A workshop brought together representatives from industry, academia and government to discuss how to improve the use of existing data, and to generate new NAMs data to derive better mechanistic understanding between humans and environmentally-relevant species, ultimately resulting in holistic chemical safety decisions. Thanks to a thorough dialogue among all participants, key challenges, current gaps and research needs were identified, and potential solutions proposed. This discussion highlighted the common objective to progress toward more predictive, mechanistically based, data-driven and animal-free chemical safety assessments. Overall, the participants recognized that there is no single approach which would provide all the answers for bridging the gap between mechanism-based human health and environmental RA, but acknowledged we now have the incentive, tools and data availability to address this concept, maximizing the potential for improvements in both human health and environmental RA.
Collapse
Affiliation(s)
- Claudia Rivetti
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Timothy E H Allen
- Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom
| | - James B Brown
- Department of Genome Dynamics Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, California 94720, USA
| | - Emma Butler
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Paul L Carmichael
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - John K Colbourne
- School of Biosciences, University of Birmingham, Birmingham B15 2TT, United Kingdom
| | - Matthew Dent
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Francesco Falciani
- Institute for Integrative Biology, University of Liverpool, L69 7ZB Liverpool, United Kingdom
| | - Lina Gunnarsson
- Biosciences, College of Life and Environmental Sciences, University of Exeter, Geoffrey Pope, Stocker Road, Exeter, Devon EX4 4QD, United Kingdom
| | - Steve Gutsell
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Joshua A Harrill
- National Center for Computational Toxicology, Office of Research & Development, U.S. Environmental Protection Agency, Mail Code B205-01, Research Triangle Park, Durham, North Carolina 27711, USA
| | - Geoff Hodges
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Paul Jennings
- Division of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - Richard Judson
- National Center for Computational Toxicology, Office of Research & Development, U.S. Environmental Protection Agency, Mail Code B205-01, Research Triangle Park, Durham, North Carolina 27711, USA
| | - Aude Kienzler
- European Commission, Joint Research Centre (JRC), Ispra, VA, Italy
| | | | - Iris Muller
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Stewart F Owen
- AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TF, United Kingdom
| | - Cecilie Rendal
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Paul J Russell
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Sharon Scott
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Fiona Sewell
- NC3Rs, Gibbs Building, 215 Euston Road, London NW1 2BE, United Kingdom
| | - Imran Shah
- National Center for Computational Toxicology, Office of Research & Development, U.S. Environmental Protection Agency, Mail Code B205-01, Research Triangle Park, Durham, North Carolina 27711, USA
| | - Ian Sorrel
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Mark R Viant
- School of Biosciences, University of Birmingham, Birmingham B15 2TT, United Kingdom
| | - Carl Westmoreland
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Andrew White
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom
| | - Bruno Campos
- Unilever, Safety and Environmental Assurance Centre, Colworth Science Park, Sharnbrook, Bedfordshire MK44 1LQ, United Kingdom.
| |
Collapse
|
57
|
Dal Negro G, Eskes C, Belz S, Bertein C, Chlebus M, Corvaro M, Corvi R, Dhalluin S, Halder M, Harvey J, Hermann M, Hoffmann-Dörr S, Kilian K, Lambrigts D, Laroche C, Louhimies S, Mahony C, Manou I, McNamee P, Prieto P, Reid K, Roggen E, Schutte K, Stirling C, Uhlrich S, Weissenhorn R, Whelan M. One science-driven approach for the regulatory implementation of alternative methods: A multi-sector perspective. Regul Toxicol Pharmacol 2018; 99:33-49. [PMID: 30098372 DOI: 10.1016/j.yrtph.2018.08.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Accepted: 08/05/2018] [Indexed: 12/28/2022]
Abstract
EU regulations call for the use of alternative methods to animal testing. During the last decade, an increasing number of alternative approaches have been formally adopted. In parallel, new 3Rs-relevant technologies and mechanistic approaches have increasingly contributed to hazard identification and risk assessment evolution. In this changing landscape, an EPAA meeting reviewed the challenges that different industry sectors face in the implementation of alternative methods following a science-driven approach. Although clear progress was acknowledged in animal testing reduction and refinement thanks to an integration of scientifically robust approaches, the following challenges were identified: i) further characterization of toxicity pathways; ii) development of assays covering current scientific gaps, iii) better characterization of links between in vitro readouts and outcome in the target species; iv) better definition of alternative method applicability domains, and v) appropriate implementation of the available approaches. For areas having regulatory adopted alternative methods (e.g., vaccine batch testing), harmonised acceptance across geographical regions was considered critical for broader application. Overall, the main constraints to the application of non-animal alternatives are the still existing gaps in scientific knowledge and technological limitations. The science-driven identification of most appropriate methods is key for furthering a multi-sectorial decrease in animal testing.
Collapse
Affiliation(s)
- Gianni Dal Negro
- GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
| | - Chantra Eskes
- SeCAM Services and Consultation on Alternative Methods, Via Campagnora 1, 6983, Magliaso, Switzerland.
| | - Susanne Belz
- European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy
| | | | - Magda Chlebus
- European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône 108, 1050, Brussels, Belgium
| | - Marco Corvaro
- ECPA - the European Crop Protection Association, 6 Avenue E. Van Nieuwenhuyse, 1160, Brussels, Belgium
| | - Raffaella Corvi
- European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy
| | - Stephane Dhalluin
- L'Oréal Research & Innovation, 9 rue Pierre Dreyfus, 92110, Clichy, France
| | - Marlies Halder
- European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy
| | - Jim Harvey
- GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
| | - Martina Hermann
- Henkel AG & Co. KGaA, Henkelstr. 67, 40589, Duesseldorf, Germany
| | | | - Karin Kilian
- European Commission, Directorate General for the Environment (DG ENV), Brussels, Belgium
| | - Denis Lambrigts
- GlaxoSmithKline Vaccines, 20 Avenue Fleming, 1300, Wavre, Belgium
| | - Charles Laroche
- European Partnership for Alternative Approaches to Animal Testing (EPAA), Av. Herrmann-Debroux 40, 1160, Brussels, Belgium
| | - Susanna Louhimies
- European Commission, Directorate General for the Environment (DG ENV), Brussels, Belgium
| | - Catherine Mahony
- The Procter & Gamble Company, Whitehall Lane, Egham, Surrey TW20 9NW, United Kingdom
| | - Irene Manou
- European Partnership for Alternative Approaches to Animal Testing (EPAA), Av. Herrmann-Debroux 40, 1160, Brussels, Belgium
| | - Pauline McNamee
- The Procter & Gamble Company, Whitehall Lane, Egham, Surrey TW20 9NW, United Kingdom
| | - Pilar Prieto
- European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy
| | - Kirsty Reid
- European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône 108, 1050, Brussels, Belgium
| | - Erwin Roggen
- 3Rs Management and Consulting, Asavænget 14, 2800, Kongens Lyngby, Denmark
| | - Katrin Schutte
- European Commission, Directorate General for the Environment (DG ENV), Brussels, Belgium
| | | | - Sylvie Uhlrich
- Sanofi Pasteur, 1541 Av. Marcel Merieux, 69280, Marcy l'Etoile, France
| | - Renate Weissenhorn
- European Commission, Directorate General for Internal Market, Industry, Enterpreneurship and SME, Brussels, Belgium
| | - Maurice Whelan
- European Commission, Joint Research Centre (JRC), Via E. Fermi 2749, 21017, Ispra, Italy
| |
Collapse
|
61
|
Myatt GJ, Ahlberg E, Akahori Y, Allen D, Amberg A, Anger LT, Aptula A, Auerbach S, Beilke L, Bellion P, Benigni R, Bercu J, Booth ED, Bower D, Brigo A, Burden N, Cammerer Z, Cronin MTD, Cross KP, Custer L, Dettwiler M, Dobo K, Ford KA, Fortin MC, Gad-McDonald SE, Gellatly N, Gervais V, Glover KP, Glowienke S, Van Gompel J, Gutsell S, Hardy B, Harvey JS, Hillegass J, Honma M, Hsieh JH, Hsu CW, Hughes K, Johnson C, Jolly R, Jones D, Kemper R, Kenyon MO, Kim MT, Kruhlak NL, Kulkarni SA, Kümmerer K, Leavitt P, Majer B, Masten S, Miller S, Moser J, Mumtaz M, Muster W, Neilson L, Oprea TI, Patlewicz G, Paulino A, Lo Piparo E, Powley M, Quigley DP, Reddy MV, Richarz AN, Ruiz P, Schilter B, Serafimova R, Simpson W, Stavitskaya L, Stidl R, Suarez-Rodriguez D, Szabo DT, Teasdale A, Trejo-Martin A, Valentin JP, Vuorinen A, Wall BA, Watts P, White AT, Wichard J, Witt KL, Woolley A, Woolley D, Zwickl C, Hasselgren C. In silico toxicology protocols. Regul Toxicol Pharmacol 2018; 96:1-17. [PMID: 29678766 DOI: 10.1016/j.yrtph.2018.04.014] [Citation(s) in RCA: 117] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2017] [Revised: 03/16/2018] [Accepted: 04/16/2018] [Indexed: 10/17/2022]
Abstract
The present publication surveys several applications of in silico (i.e., computational) toxicology approaches across different industries and institutions. It highlights the need to develop standardized protocols when conducting toxicity-related predictions. This contribution articulates the information needed for protocols to support in silico predictions for major toxicological endpoints of concern (e.g., genetic toxicity, carcinogenicity, acute toxicity, reproductive toxicity, developmental toxicity) across several industries and regulatory bodies. Such novel in silico toxicology (IST) protocols, when fully developed and implemented, will ensure in silico toxicological assessments are performed and evaluated in a consistent, reproducible, and well-documented manner across industries and regulatory bodies to support wider uptake and acceptance of the approaches. The development of IST protocols is an initiative developed through a collaboration among an international consortium to reflect the state-of-the-art in in silico toxicology for hazard identification and characterization. A general outline for describing the development of such protocols is included and it is based on in silico predictions and/or available experimental data for a defined series of relevant toxicological effects or mechanisms. The publication presents a novel approach for determining the reliability of in silico predictions alongside experimental data. In addition, we discuss how to determine the level of confidence in the assessment based on the relevance and reliability of the information.
Collapse
Affiliation(s)
- Glenn J Myatt
- Leadscope, Inc., 1393 Dublin Rd, Columbus, OH 43215, USA.
| | - Ernst Ahlberg
- Predictive Compound ADME & Safety, Drug Safety & Metabolism, AstraZeneca IMED Biotech Unit, Mölndal, Sweden
| | - Yumi Akahori
- Chemicals Evaluation and Research Institute, 1-4-25 Kouraku, Bunkyo-ku, Tokyo 112-0004 Japan
| | - David Allen
- Integrated Laboratory Systems, Inc., Research Triangle Park, NC, USA
| | - Alexander Amberg
- Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926 Frankfurt am Main, Germany
| | - Lennart T Anger
- Sanofi, R&D Preclinical Safety Frankfurt, Industriepark Hoechst, D-65926 Frankfurt am Main, Germany
| | - Aynur Aptula
- Unilever, Safety and Environmental Assurance Centre, Colworth, Beds, UK
| | - Scott Auerbach
- The National Institute of Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC 27709, USA
| | - Lisa Beilke
- Toxicology Solutions Inc., San Diego, CA, USA
| | | | | | - Joel Bercu
- Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA
| | - Ewan D Booth
- Syngenta, Product Safety Department, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6EY, UK
| | - Dave Bower
- Leadscope, Inc., 1393 Dublin Rd, Columbus, OH 43215, USA
| | - Alessandro Brigo
- Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland
| | - Natalie Burden
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London NW1 2BE, UK
| | - Zoryana Cammerer
- Janssen Research & Development, 1400 McKean Road, Spring House, PA 19477, USA
| | - Mark T D Cronin
- School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, L3 3AF, UK
| | - Kevin P Cross
- Leadscope, Inc., 1393 Dublin Rd, Columbus, OH 43215, USA
| | - Laura Custer
- Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ 08903, USA
| | | | - Krista Dobo
- Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT 06340, USA
| | - Kevin A Ford
- Global Blood Therapeutics, South San Francisco, CA 94080, USA
| | - Marie C Fortin
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 170 Frelinghuysen Rd, Piscataway, NJ 08855, USA
| | | | - Nichola Gellatly
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London NW1 2BE, UK
| | | | - Kyle P Glover
- Defense Threat Reduction Agency, Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD 21010, USA
| | - Susanne Glowienke
- Novartis Pharma AG, Pre-Clinical Safety, Werk Klybeck, CH-4057, Basel, Switzerland
| | - Jacky Van Gompel
- Janssen Pharmaceutical Companies of Johnson & Johnson, 2340 Beerse, Belgium
| | - Steve Gutsell
- Unilever, Safety and Environmental Assurance Centre, Colworth, Beds, UK
| | - Barry Hardy
- Douglas Connect GmbH, Technology Park Basel, Hochbergerstrasse 60C, CH-4057 Basel / Basel-Stadt, Switzerland
| | - James S Harvey
- GlaxoSmithKline Pre-Clinical Development, Park Road, Ware, Hertfordshire, SG12 0DP, UK
| | - Jedd Hillegass
- Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ 08903, USA
| | | | - Jui-Hua Hsieh
- Kelly Government Solutions, Research Triangle Park, NC 27709, USA
| | - Chia-Wen Hsu
- FDA Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA
| | - Kathy Hughes
- Existing Substances Risk Assessment Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada
| | | | - Robert Jolly
- Toxicology Division, Eli Lilly and Company, Indianapolis, IN, USA
| | - David Jones
- Medicines and Healthcare Products Regulatory Agency, 151 Buckingham Palace Road, London, SW1W 9SZ, UK
| | - Ray Kemper
- Vertex Pharmaceuticals Inc., Discovery and Investigative Toxicology, 50 Northern Ave, Boston, MA, USA
| | - Michelle O Kenyon
- Pfizer Global Research & Development, 558 Eastern Point Road, Groton, CT 06340, USA
| | - Marlene T Kim
- FDA Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA
| | - Naomi L Kruhlak
- FDA Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA
| | - Sunil A Kulkarni
- Existing Substances Risk Assessment Bureau, Health Canada, Ottawa, ON, K1A 0K9, Canada
| | - Klaus Kümmerer
- Institute for Sustainable and Environmental Chemistry, Leuphana University Lüneburg, Scharnhorststraße 1/C13.311b, 21335 Lüneburg, Germany
| | - Penny Leavitt
- Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ 08903, USA
| | | | - Scott Masten
- The National Institute of Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC 27709, USA
| | - Scott Miller
- Leadscope, Inc., 1393 Dublin Rd, Columbus, OH 43215, USA
| | - Janet Moser
- Chemical Security Analysis Center, Department of Homeland Security, 3401 Ricketts Point Road, Aberdeen Proving Ground, MD 21010-5405, USA; Battelle Memorial Institute, 505 King Avenue, Columbus, OH 43210, USA
| | - Moiz Mumtaz
- Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services, Atlanta, GA, USA
| | - Wolfgang Muster
- Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland
| | - Louise Neilson
- British American Tobacco, Research and Development, Regents Park Road, Southampton, Hampshire, SO15 8TL, UK
| | - Tudor I Oprea
- Translational Informatics Division, Department of Internal Medicine, Health Sciences Center, The University of New Mexico, NM, USA
| | - Grace Patlewicz
- U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC 27711, USA
| | - Alexandre Paulino
- SAPEC Agro, S.A., Avenida do Rio Tejo, Herdade das Praias, 2910-440 Setúbal, Portugal
| | - Elena Lo Piparo
- Chemical Food Safety Group, Nestlé Research Center, Lausanne, Switzerland
| | - Mark Powley
- FDA Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA
| | | | | | - Andrea-Nicole Richarz
- European Commission, Joint Research Centre, Directorate for Health, Consumers and Reference Materials, Chemical Safety and Alternative Methods Unit, Via Enrico Fermi 2749, 21027 Ispra, VA, Italy
| | - Patricia Ruiz
- Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services, Atlanta, GA, USA
| | - Benoit Schilter
- Chemical Food Safety Group, Nestlé Research Center, Lausanne, Switzerland
| | | | - Wendy Simpson
- Unilever, Safety and Environmental Assurance Centre, Colworth, Beds, UK
| | - Lidiya Stavitskaya
- FDA Center for Drug Evaluation and Research, Silver Spring, MD 20993, USA
| | | | | | - David T Szabo
- RAI Services Company, 950 Reynolds Blvd., Winston-Salem, NC 27105, USA
| | | | | | | | | | - Brian A Wall
- Colgate-Palmolive Company, Piscataway, NJ 08854, USA
| | - Pete Watts
- Bibra, Cantium House, Railway Approach, Wallington, Surrey, SM6 0DZ, UK
| | - Angela T White
- GlaxoSmithKline Pre-Clinical Development, Park Road, Ware, Hertfordshire, SG12 0DP, UK
| | - Joerg Wichard
- Bayer Pharma AG, Investigational Toxicology, Muellerstr. 178, D-13353 Berlin, Germany
| | - Kristine L Witt
- The National Institute of Environmental Health Sciences, Division of the National Toxicology Program, Research Triangle Park, NC 27709, USA
| | - Adam Woolley
- ForthTox Limited, PO Box 13550, Linlithgow, EH49 7YU, UK
| | - David Woolley
- ForthTox Limited, PO Box 13550, Linlithgow, EH49 7YU, UK
| | - Craig Zwickl
- Transendix LLC, 1407 Moores Manor, Indianapolis, IN 46229, USA
| | | |
Collapse
|